Varied opinions on thrombolysis for venous thromboembolism in infants and children: Findings from a survey of pediatric hematology-oncology specialists

Donald L. Yee, Anthony K C Chan, Suzan Williams, Neil Goldenberg, M. Patricia Massicotte, Leslie J. Raffini

Research output: Contribution to journalArticle

Abstract

Background. Recent guidelines discourage routine use of thrombolytic agents for treatment of venous thromboembolism (VTE) in pediatric patients, but actual practice patterns are unknown. Procedure. An electronic survey was emailed to all active and trainee members of the American Society of Pediatric Hematology/ Oncology in April 2008. Respondents were asked a series of multiple-choice questions based on hypothetical case scenarios describing pediatric VTE, pertinent to the implementation of thrombolytic therapy and other professional demographic information. Results. Two hundred eighty-five evaluable responses were obtained (22% response rate) which varied greatly with respect to all spheres of questioning. Tissue plasminogen activator (tPA) was the thrombolytic agent chosen by most respondents, but no clear consensus emerged as to appropriate indications (although preference for thrombolytic therapy increased with severity of the posed clinical scenario), mode of tPA delivery (systemic vs. catheter-directed), dose (high-dose vs. low-dose regimen) or a suitable maximum duration of therapy (range: 1-168 hr; varied according to specific dosing regimen chosen). Expertise in pediatric thrombosis, years out from fellowship training and volume of experience with cases of pediatric thrombosis were not largely associated with respondent choices; however, institutional experience with pharmacologic thrombolysis exhibited the most notable association of the professional demographic factors analyzed. Conclusions. The survey results support that clinical practice pertaining to use of thrombolytic agents in pediatric VTE varies widely but also provide useful benchmarks to aid clinical decision-making and future clinical trial design. Such varied practices stem from the lack of strong evidence supporting one therapeutic approach versus another.

Original languageEnglish (US)
Pages (from-to)960-966
Number of pages7
JournalPediatric Blood and Cancer
Volume53
Issue number6
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Venous Thromboembolism
Hematology
Pediatrics
Fibrinolytic Agents
Thrombolytic Therapy
Tissue Plasminogen Activator
Thrombosis
Demography
Benchmarking
Surveys and Questionnaires
Therapeutics
Catheters
Clinical Trials
Guidelines

Keywords

  • Pediatric
  • Thrombolysis
  • Thrombolytic
  • Thrombosis
  • tPA

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Varied opinions on thrombolysis for venous thromboembolism in infants and children : Findings from a survey of pediatric hematology-oncology specialists. / Yee, Donald L.; Chan, Anthony K C; Williams, Suzan; Goldenberg, Neil; Massicotte, M. Patricia; Raffini, Leslie J.

In: Pediatric Blood and Cancer, Vol. 53, No. 6, 2009, p. 960-966.

Research output: Contribution to journalArticle

Yee, Donald L. ; Chan, Anthony K C ; Williams, Suzan ; Goldenberg, Neil ; Massicotte, M. Patricia ; Raffini, Leslie J. / Varied opinions on thrombolysis for venous thromboembolism in infants and children : Findings from a survey of pediatric hematology-oncology specialists. In: Pediatric Blood and Cancer. 2009 ; Vol. 53, No. 6. pp. 960-966.
@article{e5b7c5d817284e20a3839d50d2e6345b,
title = "Varied opinions on thrombolysis for venous thromboembolism in infants and children: Findings from a survey of pediatric hematology-oncology specialists",
abstract = "Background. Recent guidelines discourage routine use of thrombolytic agents for treatment of venous thromboembolism (VTE) in pediatric patients, but actual practice patterns are unknown. Procedure. An electronic survey was emailed to all active and trainee members of the American Society of Pediatric Hematology/ Oncology in April 2008. Respondents were asked a series of multiple-choice questions based on hypothetical case scenarios describing pediatric VTE, pertinent to the implementation of thrombolytic therapy and other professional demographic information. Results. Two hundred eighty-five evaluable responses were obtained (22{\%} response rate) which varied greatly with respect to all spheres of questioning. Tissue plasminogen activator (tPA) was the thrombolytic agent chosen by most respondents, but no clear consensus emerged as to appropriate indications (although preference for thrombolytic therapy increased with severity of the posed clinical scenario), mode of tPA delivery (systemic vs. catheter-directed), dose (high-dose vs. low-dose regimen) or a suitable maximum duration of therapy (range: 1-168 hr; varied according to specific dosing regimen chosen). Expertise in pediatric thrombosis, years out from fellowship training and volume of experience with cases of pediatric thrombosis were not largely associated with respondent choices; however, institutional experience with pharmacologic thrombolysis exhibited the most notable association of the professional demographic factors analyzed. Conclusions. The survey results support that clinical practice pertaining to use of thrombolytic agents in pediatric VTE varies widely but also provide useful benchmarks to aid clinical decision-making and future clinical trial design. Such varied practices stem from the lack of strong evidence supporting one therapeutic approach versus another.",
keywords = "Pediatric, Thrombolysis, Thrombolytic, Thrombosis, tPA",
author = "Yee, {Donald L.} and Chan, {Anthony K C} and Suzan Williams and Neil Goldenberg and Massicotte, {M. Patricia} and Raffini, {Leslie J.}",
year = "2009",
doi = "10.1002/pbc.22146",
language = "English (US)",
volume = "53",
pages = "960--966",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Varied opinions on thrombolysis for venous thromboembolism in infants and children

T2 - Findings from a survey of pediatric hematology-oncology specialists

AU - Yee, Donald L.

AU - Chan, Anthony K C

AU - Williams, Suzan

AU - Goldenberg, Neil

AU - Massicotte, M. Patricia

AU - Raffini, Leslie J.

PY - 2009

Y1 - 2009

N2 - Background. Recent guidelines discourage routine use of thrombolytic agents for treatment of venous thromboembolism (VTE) in pediatric patients, but actual practice patterns are unknown. Procedure. An electronic survey was emailed to all active and trainee members of the American Society of Pediatric Hematology/ Oncology in April 2008. Respondents were asked a series of multiple-choice questions based on hypothetical case scenarios describing pediatric VTE, pertinent to the implementation of thrombolytic therapy and other professional demographic information. Results. Two hundred eighty-five evaluable responses were obtained (22% response rate) which varied greatly with respect to all spheres of questioning. Tissue plasminogen activator (tPA) was the thrombolytic agent chosen by most respondents, but no clear consensus emerged as to appropriate indications (although preference for thrombolytic therapy increased with severity of the posed clinical scenario), mode of tPA delivery (systemic vs. catheter-directed), dose (high-dose vs. low-dose regimen) or a suitable maximum duration of therapy (range: 1-168 hr; varied according to specific dosing regimen chosen). Expertise in pediatric thrombosis, years out from fellowship training and volume of experience with cases of pediatric thrombosis were not largely associated with respondent choices; however, institutional experience with pharmacologic thrombolysis exhibited the most notable association of the professional demographic factors analyzed. Conclusions. The survey results support that clinical practice pertaining to use of thrombolytic agents in pediatric VTE varies widely but also provide useful benchmarks to aid clinical decision-making and future clinical trial design. Such varied practices stem from the lack of strong evidence supporting one therapeutic approach versus another.

AB - Background. Recent guidelines discourage routine use of thrombolytic agents for treatment of venous thromboembolism (VTE) in pediatric patients, but actual practice patterns are unknown. Procedure. An electronic survey was emailed to all active and trainee members of the American Society of Pediatric Hematology/ Oncology in April 2008. Respondents were asked a series of multiple-choice questions based on hypothetical case scenarios describing pediatric VTE, pertinent to the implementation of thrombolytic therapy and other professional demographic information. Results. Two hundred eighty-five evaluable responses were obtained (22% response rate) which varied greatly with respect to all spheres of questioning. Tissue plasminogen activator (tPA) was the thrombolytic agent chosen by most respondents, but no clear consensus emerged as to appropriate indications (although preference for thrombolytic therapy increased with severity of the posed clinical scenario), mode of tPA delivery (systemic vs. catheter-directed), dose (high-dose vs. low-dose regimen) or a suitable maximum duration of therapy (range: 1-168 hr; varied according to specific dosing regimen chosen). Expertise in pediatric thrombosis, years out from fellowship training and volume of experience with cases of pediatric thrombosis were not largely associated with respondent choices; however, institutional experience with pharmacologic thrombolysis exhibited the most notable association of the professional demographic factors analyzed. Conclusions. The survey results support that clinical practice pertaining to use of thrombolytic agents in pediatric VTE varies widely but also provide useful benchmarks to aid clinical decision-making and future clinical trial design. Such varied practices stem from the lack of strong evidence supporting one therapeutic approach versus another.

KW - Pediatric

KW - Thrombolysis

KW - Thrombolytic

KW - Thrombosis

KW - tPA

UR - http://www.scopus.com/inward/record.url?scp=71049179956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049179956&partnerID=8YFLogxK

U2 - 10.1002/pbc.22146

DO - 10.1002/pbc.22146

M3 - Article

C2 - 19544387

AN - SCOPUS:71049179956

VL - 53

SP - 960

EP - 966

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -